Jaguar Health announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 16/617,466, titled Methods And Compositions For Treating Bile Acid Diarrhea, Diarrhea Associated With Small Intestine Resection Or Gallbladder Removal, And Short Bowel Syndrome.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JAGX:
- Jaguar Health reaches 75% enrollement in Phase 3 OnTarget trial of crofelemer
- Jaguar Health announces initial close in private placement financing
- Jaguar Health regains compliance with Nasdaq minimum bid price rule
- Jaguar Health, SynWorld mutually agree to terminate license agreement
- Jaguar Health engages ShareIntel to monitor trading activity
